Revenue (Tables)

9 Months Ended

Sep. 30, 2026

Revenue from Contract with Customer [Abstract]

Schedule of Disaggregation of Revenue

The following table and descriptions below show the products from which the Company generated its revenue for the periods indicated:


						Three Months Ended September 30,												Nine Months Ended September 30,
Revenue by product (in thousands)						2026						2025						2026						2025
MACI implants, kits, and instruments
Implants based on contracted rate sold through a specialty pharmacy (a)						$	49,859					$	41,090					$	141,728					$	113,086
Implants subject to third party reimbursement sold through a specialty pharmacy (b)						5,006						4,034						15,730						9,605
Implants sold direct based on contracted rates (c)						9,719						8,032						24,622						25,358
Implants sold direct subject to third-party reimbursement (d)						1,712						1,056						5,696						3,624
Biopsy kits and instruments - direct bill						606						652						1,826						1,890
Change in estimates related to prior periods (e)						470						798						(327)						1,853
Total MACI implants, kits, and instruments						67,372						55,662						189,275						155,416
Epicel
Direct bill (hospital)						12,714						10,375						34,004						23,954

NexoBrid (f)						5,285						1,466						7,974						3,971
Total revenue						$	85,371					$	67,503					$	231,253					$	183,341

(a) Represents implants sold through Orsini and AllCare whereby such specialty pharmacies have a direct contract with the underlying insurance provider. The amount of reimbursement is based on contracted rates at the time of sale supported by the pharmacy’s direct contracts.

(b) Represents implants sold through Orsini and AllCare whereby such specialty pharmacy does not have a direct contract with the underlying payer and is subject to third-party reimbursement. The amount of reimbursement is established based on publicly available rates, fee schedules or past payer precedents.

(c) Represents implants sold directly from the Company to the facility based on a contract and known price agreed upon prior to the surgery date. Also represents direct sales under a contract to specialty distributor DMS.

(d) Represents implants sold directly from the Company to the facility based on a contract and known price agreed upon prior to the surgery date. The payment terms are subject to third-party reimbursement from an underlying insurance provider.

(e) Primarily represents changes in estimates related to implants sold through Orsini or AllCare and relate to changes to the initial expected reimbursement or collection expectations upon completion of the billing claims process. The change in estimates is a result of additional information, changes in collection expectations or actual cash collections received in the current period.

(f) During the three and nine months ended September 30, 2026, the Company recognized $3.0 million of NexoBrid revenue, related to the BARDA Agreement (see Note 15, “The BARDA Agreement” for further details).